Current Edition

Digital Medication Adherence in Clinical Trials

Drug developers work tirelessly, progressing their compounds from the laboratory to the clinical phases, and rigorously assessing the medication use in Phase II and Phase III clinical trials is crucial to the future success of the treatment. Significant investment of time, resources and capital is employed in these developments, yet they are still, to a great degree, vulnerable to the risks associated with medication non-adherence. Bernard Vrijens at AARDEX Group discusses the reasons.